Global Rare Inflammatory Disease Treatment Market Report 2024

The rare inflammatory disease treatment market size has grown strongly in recent years. It will grow from $13.04 billion in 2023 to $13.82 billion in 2024 at a compound annual growth rate (CAGR) of 6%. The growth observed during the historic period can be attributed to several factors, including advances in immunology research, the emergence of targeted therapies, increased prevalence and awareness of rare inflammatory diseases, expanded utilization of biological agents, and the establishment of orphan drug regulations.

The rare inflammatory disease treatment market size is expected to see strong growth in the next few years. It will grow to $17.56 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to several factors, including accelerated drug development pipelines, increased investment in precision medicine, expanded availability of advanced diagnostics, rising prevalence and diagnosis rates of rare inflammatory diseases, and heightened efforts in patient advocacy and awareness. Key trends expected during this period include the adoption of personalized treatment approaches, integration of digital health solutions, a focus on patient-centered care, expansion of gene therapy options, and increased collaboration and data-sharing initiatives within the medical community.

The rise in autoimmune diseases is anticipated to drive the expansion of the rare inflammatory disease treatment market in the foreseeable future. Autoimmune diseases involve the immune system mistakenly attacking healthy cells and tissues, leading to inflammation and tissue damage. Factors contributing to the increase in autoimmune diseases include genetic predisposition, environmental triggers, lifestyle changes, and advancements in diagnostic techniques, resulting in improved detection and recognition of these conditions. Rare inflammatory disease treatments are commonly used to mitigate inflammation and prevent the immune system from targeting healthy tissues in patients with autoimmune disorders. For example, according to the International Osteoporosis Foundation's February 2021 report, over 300 million people worldwide suffer from rare diseases, affecting approximately 3.5% to 5.9% of the global population. Additionally, Health Match reported in November 2022 that there are approximately 150 rare kidney ailments globally, with high prevalence rates ranging from 60 to 80 incidences per 100,000 individuals in America and Europe. Hence, the increasing prevalence of autoimmune diseases is fueling the growth of the rare inflammatory disease treatment market.

Leading companies in the rare inflammatory disease treatment sector are concentrating on developing advanced precision medicines, such as monoclonal antibodies, to target specific aspects of the immune system and gain a competitive advantage. Monoclonal antibodies play a pivotal role in rare inflammatory disease treatments by focusing on particular pathways to alleviate symptoms and enhance patient outcomes. For instance, in January 2022, Boehringer Ingelheim, a pharmaceutical company based in Germany, obtained approval from the U.S. Food and Drug Administration (FDA) for SPEVIGO. This monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first approved medication for treating Generalized Pustular Psoriasis (GPP) in adults and adolescents aged 12 years and older, weighing at least 88 pounds (40 kg). SPEVIGO represents a targeted treatment approach aimed at suppressing interleukin-36 receptor (IL-36R) activity, a crucial component of an immune system signaling pathway implicated in GPP flares.

In March 2022, Pfizer Inc., a pharmaceutical company based in the United States, acquired Arena Pharmaceuticals for $6.7 billion. This strategic acquisition by Pfizer aimed to bolster its presence in the immuno-inflammatory diseases market and provide enhanced services to patients. Arena Pharmaceuticals, a U.S.-based clinical-stage company, specializes in developing innovative potential treatments for severe and rare inflammatory diseases.

Major companies operating in the rare inflammatory disease treatment market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences, Inc., Amgen Inc., Regeneron Pharmaceuticals, Inc., Biogen Inc., UCB S.A., Jazz Pharmaceuticals plc, Horizon Therapeutics plc, Kyowa Kirin Co., Ltd., BioMarin Pharmaceutical Inc., Mallinckrodt Pharmaceuticals, Sarepta Therapeutics, Inc., Cytokinetics, Incorporated, Orchard Therapeutics plc.

North America was the largest region in the rare inflammatory disease treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare inflammatory disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare inflammatory disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Rare inflammatory disease treatment encompasses a range of therapeutic interventions and strategies aimed at managing symptoms, suppressing the inflammatory response, and potentially altering the disease's course in individuals affected by these uncommon inflammatory conditions. This includes pharmacological therapies, lifestyle adjustments, supportive care measures, and participation in clinical trials or experimental treatments.

The primary drug class for rare inflammatory disease treatment consists of biologics and organic compounds. Biologics are medications derived from living organisms or their components, such as proteins, antibodies, or nucleic acids, which target specific molecules involved in the disease process. They are administered via various routes, including injectables, oral medications, among others, and are indicated for conditions such as ulcerative colitis, juvenile rheumatoid arthritis, and psoriatic arthritis. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online pharmacies.

The rare inflammatory disease treatment market research report is one of a series of new reports that provides rare inflammatory disease treatment market statistics, including the rare inflammatory disease treatment industry global market size, regional shares, competitors with rare inflammatory disease treatment market share, detailed rare inflammatory disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the rare inflammatory disease treatment industry. This rare inflammatory disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rare inflammatory disease treatment market consists of revenues earned by entities by providing services such as clinical evaluation, parallel sequencing, targeted sequencing, laboratory testing, and specialist consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare inflammatory disease treatment market also includes sales of vision evaluation instruments, blood pressure cuffs, cardiac monitors, and advanced imaging equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.